{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"305","value":"796"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Maximum plasma concentration (Cmax) of plerixafor following daily doses of 240 µg/kg plerixafor, determined directly from the concentration-time data.","dispersionType":"Standard Deviation","groups":[{"description":"Participants in the pharmacokinetic (PK) subpopulation that offered blood samples for PK analysis. Participants were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"PK Subpopulation"}],"paramType":"MEAN","populationDescription":"Participants who provided blood samples for pharmacokinetic (PK) analysis.","reportingStatus":"POSTED","timeFrame":"Day 4 (following first plerixafor administration)","title":"Maximum Observed Plasma Concentration (Cmax) on Day 4","type":"SECONDARY","unitOfMeasure":"ng/mL"}